Endpoint Health and Grifols Collaborate to Develop Antithrombin III for Sepsis

By Ayush Saxena & Lucy Haggerty

Pharma Deals Review: Vol 2022 Issue 3 (Table of Contents)

Published: 16 Mar-2022

DOI: 10.3833/pdr.v2022.i3.2677     ISSN: 1756-7874

Section: Licensing



Endpoint Health and Grifols have entered into a global licensing and collaboration agreement to develop and commercialisean Antithrombin III therapy for the treatment of sepsis...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details